SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass' Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases..

私营眼科生物技术公司 SpyGlass Pharma 宣布完成 7500 万美元的 D 轮融资。SpyGlass 的药物递送平台旨在提供多年的药物治疗，满足青光眼和其他慢性眼科疾病的长期管理需求。

The Series D was led by Sands Capital, joined by Gilde Healthcare and existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC. The funding will support the advancement of SpyGlass Pharma's cutting-edge Drug Delivery Platform through the readout of two registrational Phase III trials, set to begin later this year..

D轮融资由Sands Capital领投，Gilde Healthcare以及现有投资者New Enterprise Associates（NEA）、RA Capital、Vensana Capital、Samsara BioCapital和Vertex Ventures HC跟投。这笔资金将用于推动SpyGlass Pharma的前沿药物递送平台，通过两项注册性III期试验的数据读取，这些试验预计在今年晚些时候开始。